IRIS
SILVESTRIS, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.084
AS - Asia 4.742
EU - Europa 2.735
SA - Sud America 1.241
AF - Africa 161
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 23.976
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.896
SG - Singapore 2.349
BR - Brasile 1.096
CN - Cina 871
SE - Svezia 742
HK - Hong Kong 728
RU - Federazione Russa 586
GB - Regno Unito 252
VN - Vietnam 251
DE - Germania 215
IT - Italia 197
FR - Francia 189
IN - India 141
BE - Belgio 110
CA - Canada 90
FI - Finlandia 86
AR - Argentina 59
CI - Costa d'Avorio 58
UA - Ucraina 58
MX - Messico 56
TR - Turchia 56
ID - Indonesia 53
BD - Bangladesh 52
PL - Polonia 45
ZA - Sudafrica 42
JP - Giappone 40
CZ - Repubblica Ceca 39
IQ - Iraq 37
ES - Italia 36
AT - Austria 29
VE - Venezuela 29
NL - Olanda 23
EC - Ecuador 17
AE - Emirati Arabi Uniti 16
CO - Colombia 15
IE - Irlanda 15
IR - Iran 15
PK - Pakistan 15
BG - Bulgaria 14
LT - Lituania 14
UZ - Uzbekistan 14
IL - Israele 11
NP - Nepal 10
ET - Etiopia 9
MA - Marocco 9
RS - Serbia 9
SA - Arabia Saudita 9
CH - Svizzera 8
HR - Croazia 8
KR - Corea 8
EG - Egitto 7
KE - Kenya 7
PT - Portogallo 7
TN - Tunisia 7
CL - Cile 6
CR - Costa Rica 6
JO - Giordania 6
PY - Paraguay 6
QA - Qatar 6
RO - Romania 6
AL - Albania 5
DK - Danimarca 5
DZ - Algeria 5
HN - Honduras 5
HU - Ungheria 5
JM - Giamaica 5
KW - Kuwait 5
KZ - Kazakistan 5
LV - Lettonia 5
NO - Norvegia 5
PA - Panama 5
PE - Perù 5
AU - Australia 4
AZ - Azerbaigian 4
BH - Bahrain 4
BO - Bolivia 4
GE - Georgia 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AM - Armenia 3
AO - Angola 3
BB - Barbados 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
EE - Estonia 3
LU - Lussemburgo 3
LY - Libia 3
MT - Malta 3
MY - Malesia 3
NG - Nigeria 3
NI - Nicaragua 3
SN - Senegal 3
BW - Botswana 2
GR - Grecia 2
KG - Kirghizistan 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NR - Nauru 2
Totale 23.936
Salva come PNG Salva come JPEG
Città #
Fairfield 2.057
Ashburn 1.776
Chandler 1.769
Singapore 1.255
Woodbridge 1.034
Seattle 913
Cambridge 908
Houston 837
Hong Kong 721
Wilmington 652
Nyköping 569
Ann Arbor 397
Beijing 384
Lawrence 245
Dallas 241
Roxbury 230
Los Angeles 195
New York 162
Des Moines 146
The Dalles 120
Brussels 108
Paris 108
Columbus 104
San Diego 101
Inglewood 92
Brooklyn 91
Munich 90
Dearborn 89
São Paulo 87
Santa Clara 83
Council Bluffs 81
Jacksonville 79
Ho Chi Minh City 76
Moscow 75
London 72
Abidjan 58
Hanoi 58
Pune 55
Bari 52
Boardman 50
Jakarta 44
Chicago 42
Warsaw 41
Nanjing 40
Rio de Janeiro 39
Helsinki 37
Tokyo 37
Buffalo 34
Washington 34
Phoenix 33
San Jose 31
Turku 29
Chennai 28
Montreal 27
Brno 26
Denver 26
Edinburgh 26
San Mateo 26
Atlanta 25
Johannesburg 25
San Francisco 25
Brasília 24
Ankara 23
Belo Horizonte 23
Falls Church 23
Frankfurt am Main 23
Orem 23
Princeton 23
Stockholm 23
Dong Ket 22
Mexico City 22
Toronto 22
Poplar 21
Porto Alegre 21
Jinan 20
Ruvo Di Puglia 20
Vienna 20
Boston 19
Shanghai 18
Monmouth Junction 17
Norwalk 17
Düsseldorf 16
Guangzhou 16
Hefei 16
Amsterdam 15
Augusta 15
Dublin 15
Falkenstein 15
Rome 15
Campinas 14
Mumbai 14
Baghdad 13
Charlotte 13
Curitiba 13
Grafing 13
Jiaxing 13
Marseille 13
Nuremberg 13
Tashkent 13
Da Nang 12
Totale 17.586
Salva come PNG Salva come JPEG
Nome #
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 232
Angiogenesis in adenosquamous cancer of pancreas 197
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 177
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 172
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 163
Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma 160
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 157
Targeting angiogenesis in biliary tract cancers: An open option 152
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 150
NHERF1 and tumor microenvironment: A new scene in invasive breast carcinoma 146
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 144
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 144
Bone metastases in biliary cancers: A multicenter retrospective survey 143
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 142
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 141
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 139
Adjuvant colon cancer chemotherapy: Where we are and where we'll go 139
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 137
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 137
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 137
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 135
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 134
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 133
The European accreditation of Istituto Tumori Giovanni Paolo II of Bari 133
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 133
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 132
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 132
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms]. FT Apoptosi, o morte cellulare programmata: meccanismi regolatori e fisiopatologia. 131
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 131
Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition 130
mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma 130
Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions 129
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 129
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study 129
Adjuvant therapy in colon cancer 129
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 128
Immunotherapeutic approaches for hepatocellular carcinoma 127
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 127
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 126
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity 124
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 124
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 124
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 124
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 122
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 121
Challenges and opportunities of MicroRNAs in lymphomas 121
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 121
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 120
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 120
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis 120
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 120
Molecular classifications of gastric cancers: Novel insights and possible future applications 120
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 120
Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype 120
Co-expression of CD133+/CD44+ in human colon cancer and liver metastasis 119
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 119
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 118
Combined modality treatments in pancreatic cancer 118
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: From biological principles to clinical guidelines 118
Target therapies in pancreatic carcinoma 118
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 117
Synthetic lethality to overcome cancer drug resistance 117
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 117
Antineoplastic drug-induced bradyarrhythmias 117
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 117
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 115
Current status of targeted therapies in advanced gastric cancer 114
HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives 114
p53 as the main traffic controller of the cell signaling network 114
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 114
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 112
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 112
CES2, ABCG2, TS and topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen 112
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice 112
High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression 111
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 111
Advances in EGFR-directed therapy in head and neck cancer 111
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 110
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 110
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer 110
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma 110
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 110
Fas/Fas-ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells 109
Torch study: How much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? 109
Oncosuppressor methylation: A possible key role in colon metastatic progression 109
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma 108
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 108
Immunotherapy for colorectal cancer: where are we heading? 107
New molecular targets in bone metastases 107
Actors on the scene: Immune cells in the myeloma niche 107
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 106
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 106
Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey 106
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. 105
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy 105
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX 104
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue 104
Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers 103
The process of truth disclosure: An assessment of the results of information during the diagnostic phase in patients with cancer 103
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: A gruppo oncologico dell'Italia meridionale multicenter phase II study 102
Totale 12.513
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.884
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.884
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.677 0 0 0 0 0 330 206 254 217 285 266 119
2021/20222.210 158 210 40 77 159 151 111 133 142 113 227 689
2022/20233.704 403 517 292 362 319 414 111 475 541 26 204 40
2023/20241.173 84 216 80 103 124 324 19 66 9 28 10 110
2024/20254.596 96 83 364 208 154 517 390 427 163 224 742 1.228
2025/20265.005 1.508 411 608 847 1.292 339 0 0 0 0 0 0
Totale 24.584